ATE469966T1 - Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung - Google Patents
Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkungInfo
- Publication number
- ATE469966T1 ATE469966T1 AT01270625T AT01270625T ATE469966T1 AT E469966 T1 ATE469966 T1 AT E469966T1 AT 01270625 T AT01270625 T AT 01270625T AT 01270625 T AT01270625 T AT 01270625T AT E469966 T1 ATE469966 T1 AT E469966T1
- Authority
- AT
- Austria
- Prior art keywords
- administration
- metabolized
- adverse drug
- risk
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000376756 | 2000-12-12 | ||
PCT/JP2001/010813 WO2002048400A1 (fr) | 2000-12-12 | 2001-12-10 | Procede d'estimation du risque de l'expression d'effets secondaires causes par l'administration de compose metabolise, soit automatiquement, soit comme intermediaire metabolique, par l'enzyme ugt1a1 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE469966T1 true ATE469966T1 (de) | 2010-06-15 |
Family
ID=18845576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01270625T ATE469966T1 (de) | 2000-12-12 | 2001-12-10 | Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung |
Country Status (10)
Country | Link |
---|---|
US (4) | US20040058363A1 (de) |
EP (1) | EP1352970B1 (de) |
JP (2) | JP4447835B2 (de) |
KR (2) | KR101651391B1 (de) |
CN (1) | CN100374575C (de) |
AT (1) | ATE469966T1 (de) |
AU (1) | AU2002221112A1 (de) |
DE (1) | DE60142309D1 (de) |
ES (1) | ES2346848T3 (de) |
WO (1) | WO2002048400A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395481B1 (en) * | 1999-02-16 | 2002-05-28 | Arch Development Corp. | Methods for detection of promoter polymorphism in a UGT gene promoter |
US20030099960A1 (en) * | 2001-01-26 | 2003-05-29 | The University Of Chicago | Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity |
WO2004027088A2 (en) * | 2002-09-20 | 2004-04-01 | UNIVERSITé LAVAL | Method for determining the predisposition of patients to toxicity or lack of efficacy of a drug |
US20040203034A1 (en) * | 2003-01-03 | 2004-10-14 | The University Of Chicago | Optimization of cancer treatment with irinotecan |
DE602004014135D1 (de) | 2003-05-30 | 2008-07-10 | Univ Chicago | Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität |
BRPI0415079A (pt) * | 2003-10-06 | 2006-12-12 | Novartis Ag | biomarcadores para prognóstico de diarréia induzida por droga |
US20090247475A1 (en) * | 2004-03-05 | 2009-10-01 | The Regents Of The University Of California | Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies |
JPWO2007055261A1 (ja) * | 2005-11-10 | 2009-04-30 | 財団法人新産業創造研究機構 | Ugt1a1遺伝子多型の検査法 |
EP1790343A1 (de) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau |
GB2432365A (en) * | 2005-11-18 | 2007-05-23 | Dxs Ltd | A nucleic acid molecule for detecting polymorphisms in the UGT1A1 promoter |
JP4884899B2 (ja) * | 2006-09-19 | 2012-02-29 | 東洋鋼鈑株式会社 | イリノテカンの副作用の発生危険度を判定する方法およびそのためのキット |
KR101153058B1 (ko) | 2006-11-30 | 2012-06-04 | 아크레이 가부시키가이샤 | Ugt1a1 유전자 증폭용 프라이머 셋트, 그것을 포함하는 ugt1a1 유전자 증폭용 시약 및 그 용도 |
KR200452078Y1 (ko) * | 2009-03-10 | 2011-01-28 | 주식회사 디아이디 | 벽지샘플북의 손잡이 |
JP2011250726A (ja) * | 2010-06-01 | 2011-12-15 | Toyo Kohan Co Ltd | イリノテカンの副作用の発生危険度を判定する方法及びそのためのキット |
CN102816858B (zh) * | 2012-09-06 | 2014-02-19 | 上海源奇生物医药科技有限公司 | 一种检测ugt1a1基因型的引物和探针、及其试剂盒 |
JP6324828B2 (ja) * | 2014-07-07 | 2018-05-16 | 株式会社日立製作所 | 薬効分析システム及び薬効分析方法 |
WO2016132736A1 (ja) | 2015-02-17 | 2016-08-25 | 国立大学法人山口大学 | イリノテカンによる副作用の発生リスクの予測を補助する方法 |
CN107043808A (zh) * | 2017-01-19 | 2017-08-15 | 上海赛安生物医药科技有限公司 | Ugt1a1基因多态性检测引物肽核酸及其试剂盒 |
CN109371127A (zh) * | 2018-10-22 | 2019-02-22 | 江苏美因康生物科技有限公司 | 一种同时快速检测ugt1a1*6型与ugt1a1*28型基因多态性的试剂盒及方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
AU2224197A (en) * | 1996-03-01 | 1997-09-16 | University Court Of The University Of Dundee, The | Drug trial assay system |
AU768721B2 (en) * | 1998-04-15 | 2004-01-08 | Genset S.A. | Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma |
EP1084271A2 (de) * | 1998-05-07 | 2001-03-21 | Axys Pharmaceuticals, Inc. | Typisierung des humanen udp-glucuronosyltransferase 1 (ugt1) genes |
US6395481B1 (en) * | 1999-02-16 | 2002-05-28 | Arch Development Corp. | Methods for detection of promoter polymorphism in a UGT gene promoter |
-
2001
- 2001-12-10 ES ES01270625T patent/ES2346848T3/es not_active Expired - Lifetime
- 2001-12-10 CN CNB01822542XA patent/CN100374575C/zh not_active Expired - Lifetime
- 2001-12-10 EP EP01270625A patent/EP1352970B1/de not_active Expired - Lifetime
- 2001-12-10 KR KR1020167005073A patent/KR101651391B1/ko active IP Right Grant
- 2001-12-10 JP JP2002550114A patent/JP4447835B2/ja not_active Expired - Lifetime
- 2001-12-10 AT AT01270625T patent/ATE469966T1/de not_active IP Right Cessation
- 2001-12-10 KR KR1020037007790A patent/KR101651287B1/ko active IP Right Grant
- 2001-12-10 WO PCT/JP2001/010813 patent/WO2002048400A1/ja active Application Filing
- 2001-12-10 AU AU2002221112A patent/AU2002221112A1/en not_active Abandoned
- 2001-12-10 DE DE60142309T patent/DE60142309D1/de not_active Expired - Lifetime
-
2003
- 2003-06-12 US US10/459,729 patent/US20040058363A1/en not_active Abandoned
-
2006
- 2006-10-05 US US11/543,055 patent/US20070082357A1/en not_active Abandoned
-
2009
- 2009-05-06 US US12/453,291 patent/US20090263818A1/en not_active Abandoned
- 2009-05-29 JP JP2009129753A patent/JP4616919B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-14 US US13/026,719 patent/US20110151474A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPWO2002048400A1 (ja) | 2004-04-15 |
JP2009195247A (ja) | 2009-09-03 |
KR101651391B1 (ko) | 2016-08-25 |
KR20160031023A (ko) | 2016-03-21 |
JP4447835B2 (ja) | 2010-04-07 |
US20090263818A1 (en) | 2009-10-22 |
US20110151474A1 (en) | 2011-06-23 |
KR20030053064A (ko) | 2003-06-27 |
AU2002221112A1 (en) | 2002-06-24 |
WO2002048400A1 (fr) | 2002-06-20 |
US20040058363A1 (en) | 2004-03-25 |
EP1352970B1 (de) | 2010-06-02 |
KR101651287B1 (ko) | 2016-08-26 |
DE60142309D1 (de) | 2010-07-15 |
CN1547613A (zh) | 2004-11-17 |
EP1352970A1 (de) | 2003-10-15 |
CN100374575C (zh) | 2008-03-12 |
US20070082357A1 (en) | 2007-04-12 |
EP1352970A4 (de) | 2004-08-25 |
ES2346848T3 (es) | 2010-10-21 |
JP4616919B2 (ja) | 2011-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE469966T1 (de) | Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung | |
Selvaraj et al. | Association of vitamin D receptor genotypes with the susceptibility to pulmonary tuberculosis in female patients & resistance in female contracts | |
Labuda et al. | Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay | |
Soman et al. | Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis. | |
WO2003038123A3 (en) | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene | |
Saeki et al. | Genetic variations and haplotypes of UGT1A4 in a Japanese population | |
DE1063294T1 (de) | Dns oder gene, die an der parkinsonschen krankheit beteiligt sind | |
WO2000029623A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
ATE486956T1 (de) | T-zellrezeptor vb-db-jb-sequenz und verfahren für ihren nachweis | |
NO921798L (no) | Fremgangsmaate og reagenser for gamma-globintypebestemmelse | |
Soyama et al. | Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene | |
DE60041912D1 (de) | Polymorphe marker des lsr-gens | |
WO2004001015A3 (en) | Method for sequencing nucleic acids | |
BR0010739A (pt) | Processo de análise da predisposição genética de um paciente a pelo menos uma doença e amplificação de uma sequência e de duas sequências | |
Longo et al. | Exposure to pesticides and heterozygote genotype of GSTP1-Alw26I are associated to Parkinson's disease | |
WO2003022875A3 (en) | Polymorphisms of pd-1 | |
US20060057622A1 (en) | Low cycle amplification of RNA molecules | |
DE60040231D1 (de) | Biallelische Marker die im zusammenhang stehen mit Medikamentenmetabolismus beteiligten Genen | |
WO2004081191A3 (en) | Molecular haplotyping of genomic dna | |
AU2005264056A1 (en) | Novel allelic variant of CYP2C19 associated with drug metabolism | |
Chauhan et al. | Origin and instability of GAA repeats: insights from Alu elements | |
HUP0303632A2 (hu) | Eljárások kettős szálú DNS célszekvenciák tisztítására és detektálására hármas hélix kölcsönhatás alkalmazásával | |
Mani | UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof | |
Seiwert | The ins and outs of editing RNA in kinetoplastids | |
WO2002006294A3 (en) | Haplotypes of the mmp13 gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |